Geovax Labs Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.1%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$8.70next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
GEO-MVA Phase 3 Trial Initiation QuarterlyTarget: Initiation of pivotal Phase 3 immunobridging trial in H2 2026
Cash Runway and Liquidity Quarterly1.3MTarget: Secure additional non-dilutive or dilutive capital to extend runway beyond mid-2026
Gedeptin Clinical Progress AnnuallyTarget: Initiation of Phase 2 combination trial in head and neck cancer in 2027
Watch Items
- Going Concern Status and Capital DilutionTrigger: Cash balance falling below $1.0 million without committed fundingAction: Monitor warrant exercises, PIPE transactions, and potential strategic partnerships to mitigate going concern risk.
- GEO-MVA Regulatory MilestonesTrigger: Delays in Phase 3 trial startup or protocol alignment with the EMA/FDAAction: Re-evaluate clinical timelines and adjust operational cash burn projections.
Research as of 20 Jun 2026